COMP <GO>
TWST vs LLY // FORWARD P/E MULTIPLE
Twist Bioscience Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: TWST 4
— LLY 10
▲ FORWARD P/E MULTIPLE LEADER: TWST
LAST: $152.78 (-11.92%) • MKT CAP: $11.50B
forward-pe
21.0x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 83.64% | +10.56 | TWST | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 32.36% | -44.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 2.30% | -2.96 | LLY | /fcf-yield <GO> |
| Operating Margin | -4.20% | 40.21% | -44.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 31.90% | -34.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 45.51% | -29.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 9.29 | +16.71 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.77% | +0.03 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.2 | 77.9 | -28.64 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.51 | +0.47 | TWST | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 21.0x | 26.3x | -5.25 | TWST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.50B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | LLY REV | TWST GROSS % | LLY GROSS % | TWST FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$75.6M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | -$69.2M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$142.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
LLY // BETA 0.51